Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effectiveness of High-Dose Synthetic BH4 (Saproterin Dihydrochloride or "Kuvan") in Amish PKU Patients

NCT02677870 is registered in ClinicalTrials.gov with University Hospitals Cleveland Medical Center as lead sponsor.

NCT NCT02677870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02677870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effectiveness of High-Dose Synthetic BH4 (Saproterin Dihydrochloride or "Kuvan") in Amish PKU Patients
Lead sponsor
University Hospitals Cleveland Medical Center
Phase
Phase 4
Overall status
Completed
Start date
January 22, 2018
Completion date
January 1, 2019
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

phenylketonuria